Cellulitis from Spider Bite: Bacterial Pathogens and Antibiotic Regimen
For cellulitis following a spider bite, treat empirically for MRSA (methicillin-resistant Staphylococcus aureus) in addition to streptococci, as MRSA is isolated in 87% of spider bite-associated soft tissue infections requiring surgical intervention.
Primary Bacterial Pathogen
The dominant pathogen in spider bite-associated cellulitis is Staphylococcus aureus, with MRSA representing the overwhelming majority of cases. In a surgical series of 38 patients with serious soft tissue infections from spider bites, 100% grew S. aureus, and 86.8% were methicillin-resistant 1. This finding is reinforced by recent case reports documenting MRSA superinfection complicating brown recluse spider bites 2.
While streptococci remain important pathogens in typical cellulitis 3, spider bites represent a penetrating trauma scenario that fundamentally changes the microbiology and requires broader coverage.
Antibiotic Selection and Dosing
For Outpatient Management (Mild-Moderate Cases):
Recommended regimens active against both MRSA and streptococci:
Trimethoprim-sulfamethoxazole (TMP-SMX): 1-2 double-strength tablets (160/800 mg) PO twice daily
- All isolated organisms in the surgical series were sensitive to TMP-SMX 1
- Must add coverage for streptococci (e.g., amoxicillin 500 mg PO three times daily or cephalexin 500 mg PO four times daily)
Doxycycline: 100 mg PO twice daily
- Provides both MRSA and streptococcal coverage
- Single-agent option
Clindamycin: 300-450 mg PO three to four times daily
- Covers both MRSA and streptococci
- Check local resistance patterns (inducible resistance possible)
For Inpatient Management (Severe Cases with SIRS):
Vancomycin: 15-20 mg/kg IV every 8-12 hours (target trough 15-20 mcg/mL)
- First-line for severe MRSA infections 3
For necrotizing infection: Vancomycin PLUS piperacillin-tazobactam (3.375 g IV every 6 hours) or a carbapenem 3
Treatment Duration
5 days minimum, extending treatment if infection has not improved within this timeframe 3. Given the high rate of treatment failure with initial penicillin-based therapy (29% in one series 1), reassess at 48-72 hours and adjust based on clinical response.
Critical Clinical Decision Points
When to Cover MRSA (Spider Bite Context):
Spider bites constitute penetrating trauma and should trigger MRSA coverage according to IDSA guidelines 3. Additional factors strengthening this indication include:
- Purulent drainage
- Failed initial penicillin-based therapy
- Systemic signs (fever, SIRS)
- Abscess formation
When to Pursue Surgical Intervention:
The mean time to surgical evaluation in the series was 5 days, with mean excised tissue size of 26 cm² 1. Do not delay surgical consultation if:
- Progressive erythema despite 48 hours of antibiotics
- Fluctuance or abscess formation
- Severe pain out of proportion to examination
- Systemic toxicity
- Necrotic tissue
Obtain Cultures When:
Blood cultures and wound cultures (via aspiration, biopsy, or surgical specimen) are indicated for spider bite cellulitis given the penetrating trauma mechanism 3. This is critical because:
- 29% failed initial outpatient therapy 1
- Antibiotic adjustment based on culture data is essential
- MRSA prevalence is extremely high in this population
Common Pitfalls
Assuming typical cellulitis microbiology: Standard streptococcal coverage alone (penicillin, cephalexin) will fail in 87% of cases requiring intervention 1
Delaying surgical evaluation: Mean time to surgery was 5 days in one series—earlier intervention may prevent extensive debridement 1
Misdiagnosis: Many presumed "spider bites" are actually primary staphylococcal infections or other conditions 4. However, when true cellulitis is present following witnessed spider bite, MRSA coverage is mandatory.
Inadequate duration: The 5-day minimum from IDSA guidelines 3 applies, but spider bite infections often require longer courses given tissue destruction and treatment failure rates.